Cancer Immunology Reserch

Cancer Immunol Res. 2025 Sep 4. doi: 10.1158/2326-6066.CIR-25-0488. Online ahead of print. ABSTRACT Tumor-associated macrophages (TAMs) display remarkable functional heterogeneity, yet the molecular mechanisms driving their diverse phenotypes remain elusive. Using CRISPR screens in primary macrophages, we identified tumor-derived factors, including lactic acid, PGE2, and GM-CSF, as key modulators of TAM polarization. These factors interact … Read more

Cancer Immunol Res. 2025 Sep 4. doi: 10.1158/2326-6066.CIR-24-1074. Online ahead of print. ABSTRACT Liver metastases are associated with poor cancer outcomes in many solid malignancies, but the factors influencing the trajectory of patients with liver metastases are poorly defined. It is known that liver metastases suppress systemic antitumor immunity; however, the underlying mechanisms remain incompletely … Read more

Cancer Immunol Res. 2025 Sep 4. doi: 10.1158/2326-6066.CIR-25-0086. Online ahead of print. ABSTRACT The discovery of immune checkpoints and the rapid growth of immuno-oncology (IO) have sparked efforts to utilize the immune system to treat a wide range of cancer types/subtypes. While the major focus of IO over the past decades has been to manipulate … Read more

Cancer Immunol Res. 2025 Sep 2;13(9):1325. doi: 10.1158/2326-6066.CIR-13-9-WWR. NO ABSTRACT PMID:40891195 | DOI:10.1158/2326-6066.CIR-13-9-WWR

Cancer Immunol Res. 2025 Sep 1. doi: 10.1158/2326-6066.CIR-24-1228. Online ahead of print. ABSTRACT Combination chemotherapy and immunotherapy are effective against advanced gastric cancer (GC). However, T cell exhaustion in the tumor microenvironment may decrease the immune response and compromise the effectiveness of immunotherapy. Herein, we report the potential role of EBI3 in promoting T cell … Read more

Cancer Immunol Res. 2025 Sep 1. doi: 10.1158/2326-6066.CIR-25-0149. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy against hematologic malignancies but has struggled to achieve comparable success in solid tumors. A key obstacle in solid tumors is the extracellular matrix (ECM), which impedes CAR T-cell infiltration. In clinical trials, … Read more

Cancer Immunol Res. 2025 Aug 29. doi: 10.1158/2326-6066.CIR-25-0083. Online ahead of print. ABSTRACT Polymerase epsilon mutant (POLE-mut) endometrial cancers (EC) are characterized by a near 100% disease-specific survival rate, even when treated by surgery alone. This spectacular survival, combined with the ultramutated genome and high level of neoantigens in these tumors, indicates a substantial degree … Read more

Cancer Immunol Res. 2025 Aug 29. doi: 10.1158/2326-6066.CIR-25-0047. Online ahead of print. ABSTRACT Immunotherapy has emerged as a promising treatment for head and neck squamous cell carcinoma (HNSCC), yet clinical responses remain limited. Elevated expression of interferon-stimulated gene 15 (ISG15), commonly observed in oral squamous cell carcinoma (OSCC), may contribute to this limited efficacy. Although … Read more

Cancer Immunol Res. 2025 Aug 28. doi: 10.1158/2326-6066.CIR-25-0159. Online ahead of print. ABSTRACT Myeloid cells – including monocytes, macrophages, dendritic cells, and granulocytes – are critical architects of the tumor microenvironment, where they exert diverse functions ranging from immunosuppressive to immunostimulatory. Advances in single-cell omics and high-dimensional immune profiling have unveiled the remarkable heterogeneity and … Read more

Cancer Immunol Res. 2025 Aug 28. doi: 10.1158/2326-6066.CIR-25-0491. Online ahead of print. ABSTRACT Advanced sarcomas have limited treatment options after standard therapy, and therefore we investigated the efficacy and safety of sintilimab plus anlotinib in this setting. Patients aged 18-75 years with advanced sarcomas and prior systemic therapy were enrolled. Patients with untreated, primary chemotherapy-resistant … Read more